Beta Bionics(BBNX)

Focus: Beta Bionics is a public biotech company focused on artificial pancreas technology, specifically the iLet Bionic Pancreas system for diabetes management. With 1-50 employees and $65M in FY 2025 revenue, it operates as a specialized medical device and software company in the gastroenterology/endocrinology space.

Gastroenterology

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1-50

Open Jobs

25-3 this month

Stable — net -3 jobs in 30d

8 added, 11 removed. Backfill posture.

Should You Work at Beta Bionics?

AI assessment

Best suited for commercial, regulatory, or supply chain professionals seeking high-growth opportunity; less attractive for R&D scientists due to narrow pipeline focus and financial burn rate.

Why Work Here

Focused pipeline with 2 Phase 3 programs (iLet Bionic Pancreas for CF-related diabetes, bihormonal iLet for Type 1 diabetes) approaching regulatory inflection points

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$65M

Key Products

iLet Bionic Pancreas System

Cystic Fibrosis-related Diabetes

Growth

Phase 3 lead program with potential regulatory approval pathway; addresses underserved CF-related diabetes population.

Bihormonal iLet Bionic Pancreas

Type 1 Diabetes Mellitus

Help build intelligence for Beta Bionics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Rapid revenue growth trajectory—$65M in FY 2025 vs. $12M in FY 2024 (442% YoY)—signals commercial traction and team expansion

Heavy commercial hiring (19 of 28 active roles) indicates pre-launch or early-market-entry momentum requiring skilled go-to-market talent

Watch Out For

Company is burning cash: $-54.8M net loss in FY 2025 despite revenue growth, with only $30M cash on hand—runway sustainability is unclear
Minimal R&D hiring (1 of 28 roles) signals the company prioritizes commercial execution over discovery, limiting scientific career depth
No published clinical literature (0 publications tracked), no NIH funding, and reliance on a single therapeutic area (diabetes) concentrates career risk

Generated by Claude from Beta Bionics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Phase 2/3 program expanding addressable market to broader Type 1 diabetes population; dual-hormone formulation differentiates from competitors.

Insulin Lispro

Diabetes Mellitus, Type 1

Growth

Phase 2 program supporting iLet platform integration; proprietary insulin formulation may enable device-drug synergies.

Pipeline & Clinical Trials

Bionic Pancreas

Diabetes Mellitus, Type 1

N/A

Bionic Pancreas

Type 1 Diabetes (T1D)

N/A

Bionic Pancreas

Diabetes Mellitus

N/A

Clinical Trials (1)

NCT04200313The Insulin-Only Bionic Pancreas Pivotal Trial

N/A

Bionic Pancreas

Cystic Fibrosis-related Diabetes

N/A

Clinical Trials (1)

NCT03258853Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

N/A

iLet Dosing Decision Software

Type 1 Diabetes

N/A

Clinical Trials (1)

NCT06891898The iLet Experience Study

N/A

GlucoSTAT

Type 1 Diabetes

N/A

Clinical Trials (1)

NCT04227626Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

N/A

Insulin Lispro

Diabetes Mellitus, Type 1

PHASE_2

Clinical Trials (1)

NCT02971228Feasibility Trial Testing the Bionic Pancreas With ZP4207

Phase 2

Bihormonal iLet Bionic Pancreas

Type 1 Diabetes Mellitus

PHASE_2_3

Clinical Trials (1)

NCT03840278The Bihormonal iLet Bionic Pancreas Feasibility Study

Phase 2/3

iLet Bionic Pancreas System

Cystic Fibrosis-related Diabetes

PHASE_3

Clinical Trials (1)

NCT06449677Bionic Pancreas in CFRD

Phase 3

Interview Prep Quick Facts

Portfolio: 7 clinical trials

Top TAs: Metabolic Diseases, Rare Diseases

SEC Filings: 2 available

Open Roles: 25 active jobs

Therapeutic Area Focus

Metabolic Diseases

5 pipeline

Rare Diseases

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$65M443%

R&D Spend

$26M(40%)46%

Net Income

-$55M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Beta Bionics(BBNX)

Should You Work at Beta Bionics?

Why Work Here

Key Products

Watch Out For

Pipeline & Clinical Trials

Open Jobs (25)

Territory Business Manager - Seattle / Tacoma

Territory Business Manager - Charlotte, NC

Territory Business Manager - Boston North

Clinical Affairs Lead

Senior Manufacturing Test Engineer

Territory Business Manager - Boston, MA

Territory Business Manager - Denver (North), CO

Territory Business Manager - Dayton, OH

Territory Business Manager - Lexington, KY

Territory Business Manager - Dallas, TX

Clinical Diabetes Specialist - Alabama

Clinical Diabetes Specialist - St. Louis (North), MO

Territory Business Manager - Maryland / Delaware

Senior Data Analyst, Clinical & Commercial Analytics

Clinical Diabetes Specialist - Seattle / Tacoma, WA

Clinical Diabetes Specialist - State College, PA

Territory Business Manager - Salt Lake City, UT

Clinical Diabetes Specialist - Roanoke, VA

Territory Business Manager - Roanoke, VA

Territory Business Manager - Lancaster, PA

Assembler I

Assembler I - Weekend Swing Shift

Assembler II - Weekend Swing Shift

Assembler II

Assembler III

Financials (FY2025)

Hiring Trend